Log in to save to my catalogue

Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, dou...

Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, dou...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_02904617v1

Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study

Publication information

Publisher

United States: Elsevier Ltd

More information

Scope and Contents

Contents

Long-term protection and herd immunity induced by existing pertussis vaccines are imperfect, and a need therefore exists to develop new pertussis vaccines. This study aimed to investigate the safety, colonisation, and immunogenicity of the new, live attenuated pertussis vaccine, BPZE1, when given intranasally.
This phase 1b, double-blind, random...

Alternative Titles

Full title

Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_inserm_02904617v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_02904617v1

Other Identifiers

ISSN

1473-3099

E-ISSN

1474-4457

DOI

10.1016/S1473-3099(20)30274-7

How to access this item